Oncolytic Virus Immunotherapy
Marchini, Antonio
Oncolytic Virus Immunotherapy - Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 - 1 electronic resource (366 p.)
Open Access
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
Creative Commons
English
books978-3-0365-2548-8 9783036525495 9783036525488
10.3390/books978-3-0365-2548-8 doi
Medicine
Clinical & internal medicine
oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy n/a
Oncolytic Virus Immunotherapy - Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 - 1 electronic resource (366 p.)
Open Access
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
Creative Commons
English
books978-3-0365-2548-8 9783036525495 9783036525488
10.3390/books978-3-0365-2548-8 doi
Medicine
Clinical & internal medicine
oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy n/a